05.01.2019 | Editorial
Chronic use of pentosan polysulfate sodium associated with risk of vision-threatening disease
verfasst von:
Tanner J. Ferguson, Ryan L. Geraets, Matthew A. Barker
Erschienen in:
International Urogynecology Journal
Einloggen, um Zugang zu erhalten
Excerpt
A recent article in
Ophthalmology in May 2018 by Pearce et al. uncovered a potential vision-threatening complication associated with the long-term use of pentosane polysulfate sodium (PPS), an established treatment for interstitial cystitis and the only FDA-approved oral option, sold under the brand name Elmiron [
1]. The authors should be commended for their work and we encourage the review of their initial report [
2]. …